Galeterone (VN 124) is an orally active small molecule that antagonizes the androgen receptor, inhibits CYP17A1 lyase activity, and reduces androgen receptor protein levels, thereby suppressing androgen signaling in prostate cancer. It is used in research for studying castration-resistant prostate cancer mechanisms and has been evaluated in both in vitro assays and in vivo xenograft models.